Several targeted treatments, such as venetoclax + obinutuzumab (VenO) and ibrutinib, have emerged to treat treatment-naïve patients with chronic lymphocytic leukemia (CLL) and have been shown to improve progression-free survival (PFS) compared to chlorambucil + obinutuzumab (ClbO). However, novel targeted agents are associated with a significant cost investment. The objective of this study was to investigate the cost-effectiveness of VenO compared to ClbO and ibrutinib in treatment-naïve CLL without del17p/TP53 mutation in Denmark. We employed a decision analytic modeling approach to simulate hypothetical cohorts of patients with CLL patients from initiation of first-line treatment until death, including the full treatment pathway and second-line therapy. VenO, ClbO, or ibrutinib was included as first-line therapy followed by either Ven plus rituximab or ibrutinib. Model outcomes were expected quality-adjusted life-years (QALYs), life-years (LYs), and cost per patient, which were used to calculate incremental cost-effectiveness ratios (ICERs) with a willingness to pay of EUR 23,600-35,600 per QALY. Compared with ClbO, VenO was associated with a QALY gain of 1.30 (1.42 LYs) over a lifetime. The incremental cost was €12,360, resulting in an ICER of €9,491/QALY gained, indicating VenO is cost-effective. Compared with VenO, ibrutinib was associated with a QALY gain of 0.82 (1.74 LYs) but at a substantially increased incremental cost of €247,488 over a lifetime horizon. The ICER was €302,156/QALY, indicating that ibrutinib in first-line treatment would not be considered cost-effective in Danish healthcare compared to VenO. Future analyses in fit patients with CLL patients are needed to determine the cost-effectiveness of VenO. -
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.